Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Clinical Pharmadynamics of Evolocumab

Clin Pharmacokinet; ePub 2018 Jan 20; Kasichayanula, et al

The pharmacodynamic effects of PCSK9 inhibitor evolocumab are rapid, with maximum suppression within 4 hours, according to a recent review of the clinical pharmacokinetics and pharmacodynamics. The review also found:

  • Evolocumab exhibits nonlinear kinetics and a half-life of 11 to 17 days.
  • With maximal suppression of PCSK9 occurring within 4 hours, peak reduction of LDL-C, ranging from 55 to 75%, occurs ~1-2 weeks after a dose of evolocumab.
  • Patient-specific factors do not have a clinically meaningful effect on the pharmacodynamic effects of evolocumab; thus, no dose adjustment is necessary based on patient-specific factors of concomitant medication use.
  • When combined with a statin, evolocumab can result in additional lowering of LDL-C.

Citation:

Kasichayanula S, Grover A, Emery MG, et al. Clinical pharmacokinetics and pharmacodynamics of evolocumab, a PCSK9 inhibitor. [Published online ahead of print January 20, 2018]. Clin Pharmacokinet. doi:10.1007/s40262-017-0620-7.

This Week's Must Reads

Lipid Testing After Acute Myocardial Infarction, J Am Heart Assoc; ePub 2018 Jan 25; Wang, et al

Clinical Pharmadynamics of Evolocumab, Clin Pharmacokinet; ePub 2018 Jan 20; Kasichayanula, et al

Lipoproteins & CV Outcomes in Dialysis Patients, J Clin Lipidol; ePub 2017 Dec 26; Kaysen, et al

Is Dual Lipid-Lowering Therapy Better?, Atherosclerosis; 2018 Feb; Gragnano, et al

sLOX-1 in Ischemic Stroke & Transient Ischemic Attack, J Am Heart Assoc; ePub 2018 Jan 12; Skarpengland, et al

Must Reads in Hypercholesterolemia

Lipid Testing After Acute Myocardial Infarction, J Am Heart Assoc; ePub 2018 Jan 25; Wang, et al

Clinical Pharmadynamics of Evolocumab, Clin Pharmacokinet; ePub 2018 Jan 20; Kasichayanula, et al

Lipoproteins & CV Outcomes in Dialysis Patients, J Clin Lipidol; ePub 2017 Dec 26; Kaysen, et al

Is Dual Lipid-Lowering Therapy Better?, Atherosclerosis; 2018 Feb; Gragnano, et al

sLOX-1 in Ischemic Stroke & Transient Ischemic Attack, J Am Heart Assoc; ePub 2018 Jan 12; Skarpengland, et al